A new drug compound could combat tough-to-treat melanoma
Melanoma is commonly caused by the damaging effects of ultraviolet light—from sources like sunlight and tanning beds—on the DNA of skin cells. This UV damage can activate genes that encourage precancerous cells to further mutate into full-blown skin cancer. At the same time, UV damage can turn off other genes that would normally prevent tumor growth. With enough wrongly flipped switches, cancer can flourish. And melanoma is certainly flourishing. This year alone, 96,480 new instances of melanoma will be diagnosed in the United States and 7,230 Americans will die from the disease.
With so many people affected by melanoma, scientists are on the hunt for better ways to screen for melanoma risk and treat the most lethal types of skin cancer. One particularly voracious type of melanoma, caused by mutation of a gene called NRAS (which instructs cells to produce a protein of the same name, NRAS), drives 25 percent of skin cancers.
“There are immunotherapies and targeted therapies that have shown huge improvements for patients with melanoma,” said Rutao Cui, a Boston University School of Medicine professor of pharmacology and dermatology. “However, for patients with NRAS mutations, they don’t have very useful or very effective treatment strategies.”
Now, an international research team led by Cui has discovered a new way to stop the progression of melanoma by NRAS mutations with the flip of a genetic switch. Their findings were published January 31, 2019, in Cell.
Inside our bodies, proteins like NRAS play the role of dominoes, interacting with one another to switch other important gene activities on or off. The researchers set out in search of a way to interrupt the process in which mutated NRAS can instigate the growth of skin cancer. Since targeting the NRAS gene—just one of several dominoes in this type of skin cancer pathway—has proven to be so difficult, the researchers were determined to find another approach.
For NRAS to trigger cancer development, it first needs to be activated by another protein in the body. Until now, it’s been unknown exactly which protein is responsible for activating NRAS. But after testing the effect of several different proteins on the activity of NRAS, the team zeroed in on a likely culprit, a protein by the name of STK19.
STK19 is not a newly discovered protein in its own right, but its purpose has not been known until now. Cui’s team found that STK19 appears to work as an “on” switch for NRAS—activating production of NRAS proteins which, in turn, trigger the toppling of several other genetic dominoes downstream.
The researchers also found that, unlike NRAS, they could disable the STK19 gene and greatly diminish its ability to set the skin cancer sequence in motion.
Together, the team designed a new drug compound to shut down the effect of STK19 on NRAS. Then, testing its effect on skin cells cultured in petri dishes and in animal models, they proved that their compound can block NRAS activation and prevent melanoma from developing.
Cui says that this result is exciting not just for melanoma, but for other cancers as well. While the relationship between STK19 and NRAS may be particular to skin cancer, the approaches the team used to identify and block key activating proteins can be applied to find new treatments for similarly difficult-to-cure cancers.
Now the research team is looking to take their research to clinical trials to test out the STK19 inhibitor in humans, and hopefully, someday make it available as a targeted therapy to combat NRAS-driven melanomas.
In the meantime, Cui says that much work still needs to be done to not only create better and more precise treatments for patients suffering with melanoma, but also to alert vulnerable populations about the risk factors associated with the cancer.
“We need more monitoring for early diagnosis and full-body examinations for problematic spots,” says Cui, “and more proactive strategies for patients [at the highest risk of developing melanoma] to prevent cancer progression and metastasis.”
Learn more: Shutting Down Skin Cancer
The Latest on: Skin cancer
[google_news title=”” keyword=”skin cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Skin cancer
- 6 symptoms of skin cancer everyone should know abouton May 13, 2024 at 11:30 am
Skin cancer, a prevalent yet preventable disease, can be identified through various signs like changes in moles, new growths, non-healing sores, and t ...
- Skin Cancer Awareness Month: Doctors Emphasize the Importance of Sunscreen Usageon May 13, 2024 at 11:15 am
SAN ANTONIO – May marks National Skin Cancer Awareness Month and doctors at the START Center for Cancer Care say the biggest way to protect yourself against the disease is to wear sunscreen. “Sunburns ...
- Protecting your skin: Facts and prevention tips for skin canceron May 13, 2024 at 10:34 am
Ultimate comfort and style this summer with Walking Comfort, a destination for the best footwear. Their large selection of Dansko shoes ...
- Merck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatmenton May 13, 2024 at 10:09 am
Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial evaluates the investigational coformulation ...
- Merck stopped a clinical trial for its experimental skin cancer drug after a high rate of side effectson May 13, 2024 at 9:31 am
Merck announced Monday that it is pulling the plug on its phase 3 trial of an experimental combination treatment for skin cancer after side effects of the medication led patients to drop out of the ...
- Springfield doctor shares tips on how to prevent skin cancer for Skin Cancer Awareness Monthon May 13, 2024 at 8:09 am
May is Skin Cancer Awareness Month, and it’s a good time to remember what to look for and how to prevent skin cancer.
- Sun safety tips to reduce skin cancer riskon May 13, 2024 at 3:12 am
Titanium dioxide and zinc oxide protect users by blocking the sun’s harmful UV rays, causing them to reflect off the skin. Plus, because they’re minerals and not chemicals, they can reduce the risk of ...
- Merck stops skin cancer combination therapy testing in late-stage studyon May 13, 2024 at 3:09 am
Merck said on Monday it had discontinued the arm of a late-stage study, which tested an experimental antibody-based drug with its blockbuster immunotherapy Keytruda for some patients with the most ...
- Labour MP Chris Bryant being treated after skin cancer detected in his lungon May 13, 2024 at 2:48 am
Minister, who had treatment for condition five years ago, says melanoma was found during routine scan in January ...
- Labour MP Chris Bryant's warning after being diagnosed with skin cancer in lungon May 13, 2024 at 1:30 am
A Labour MP on Monday warned the public to “take skin cancer seriously” as he revealed he had been diagnosed with melanoma in his lung. Sir Chris Bryant said he was first diagnosed with a ...
via Bing News